Literature DB >> 11254398

Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.

B A Graff1, I Bjørnaes, E K Rofstad.   

Abstract

The effective microvascular permeability of human melanoma xenografts to albumin-Evans blue was measured and related to tumor volumetric growth rate, rate of tumor angiogenesis, and expression of vascular endothelial growth factor (VEGF) in an attempt to identify mechanisms regulating the microvascular permeability of tumors to macromolecules. Three melanoma lines (A-07, R-18, and U-25) were included in the study. Effective microvascular permeability was assessed by using the indicator diffusion method. Intradermal and intratumor angiogenesis assays were used to measure the rate of tumor angiogenesis. VEGF expression was studied by ELISA, immunohistochemistry, Western blotting, and measurement of tumor-induced formation of ascitic fluid. The effective microvascular permeabilities of albumin-Evans blue were determined to be (1.5 +/- 0.2) x 10(-6) cm/s (A-07), (1.1 +/- 0.4) x 10(-6) cm/s (R-18), and (0.9 +/- 0.3) x 10(-6) cm/s (U-25). These values are high compared with those measured for other tumor lines and are not significantly different. Correlations between the effective microvascular permeability of albumin-Evans blue and tumor volumetric growth rate, rate of tumor angiogenesis, or VEGF expression were not found. The three last-mentioned parameters differed significantly among the melanoma lines and covered a broad range of values relative to those of other experimental tumors. Our study suggests that the effective microvascular permeability of macromolecules can be high even in slowly growing tumors, poorly angiogenic tumors, and tumors showing low VEGF expression. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254398     DOI: 10.1006/mvre.2001.2303

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  9 in total

1.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

3.  Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.

Authors:  Anil Potti; Nauman Moazzam; Eric Langness; Kaley Sholes; Ketki Tendulkar; Michael Koch; Steve Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-21       Impact factor: 4.553

4.  A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo.

Authors:  Fan Lü; Zhao-Yin Qin; Wen-Bin Yang; Yin-Xin Qi; Yi-Min Li
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

5.  Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts.

Authors:  B A Graff; Y Kvinnsland; A Skretting; E K Rofstad
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

6.  Elucidation of the tumoritropic principle of hypericin.

Authors:  M Van de Putte; T Roskams; J R Vandenheede; P Agostinis; P A M de Witte
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

7.  Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography.

Authors:  Haojun Chen; Xiao Tong; Lixin Lang; Orit Jacobson; Bryant C Yung; Xiangyu Yang; Ruiliang Bai; Dale O Kiesewetter; Ying Ma; Hua Wu; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2017-06-14       Impact factor: 11.556

8.  Bevacizumab treatment of meningeal melanoma metastases.

Authors:  Trude G Simonsen; Jon-Vidar Gaustad; Einar K Rofstad
Journal:  J Transl Med       Date:  2020-01-08       Impact factor: 5.531

9.  Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts.

Authors:  Ruixia Huang; Lise Mari K Andersen; Einar K Rofstad
Journal:  J Transl Med       Date:  2017-10-10       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.